Patents by Inventor Simon ALVIS

Simon ALVIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GROUP B ADENOVIRUS-CONTAINING FORMULATION
    Publication number: 20240398879
    Abstract: The present disclosure relates to formulations suitable for the storage of group B adenoviruses, such as Enadenotucirev (EnAd), processes for making the formulations, and use of the formulations in methods of treatment.
    Type: Application
    Filed: April 18, 2024
    Publication date: December 5, 2024
    Inventors: Simon ALVIS, Magdalena KIELTYKA
  • Group B adenovirus-containing formulation
    Patent number: 11998580
    Abstract: The present disclosure provides a liquid formulation suitable for a group B adenovirus, comprising: a) a group B adenovirus, such as replication competent group B adenovirus, b) 15 to 25% v/v glycerol, for example 16, 17, 18, 19, 20, 21% v/v glycerol; and c) 0.1 to 1.5% v/v ethanol, for example 0.2-1%, such as 1% v/v ethanol; and d) a buffer, and e) optionally an amino acid, wherein the pH of the formulation is in the range 8.0 to 9.6, and use of the same in treatment, particular in the treatment of cancer.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: June 4, 2024
    Assignee: AKAMIS BIO LIMITED
    Inventors: Simon Alvis, Magdalena Kieltyka
  • METHOD OF PURIFYING A COMPOSITION COMPRISING A GROUP B ADENOVIRUS
    Publication number: 20220340885
    Abstract: A method of purifying a composition comprising a group B adenovirus, for example comprising a purification step of: subjecting a composition comprising said group B adenovirus to diafiltration employing a diafiltration-buffer with a conductivity of at least 180 mScm?1, for example a conductivity of 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, or 290 mScm?1. Also provided is a composition obtained using the purification method disclosed herein.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 27, 2022
    Inventors: Peter CLARKE, Simon ALVIS
  • GROUP B ADENOVIRUS-CONTAINING FORMULATION
    Publication number: 20210121512
    Abstract: The present disclosure provides a liquid formulation suitable for a group B adenovirus, comprising: a) a group B adenovirus, such as replication competent group B adenovirus, b) 15 to 25% v/v glycerol, for example 16, 17, 18, 19, 20, 21% v/v glycerol; and c) 0.1 to 1.5% v/v ethanol, for example 0.2-1%, such as 1% v/v ethanol; and d) a buffer, and e) optionally an amino acid, wherein the pH of the formulation is in the range 8.0 to 9.6, and use of the same in treatment, particular in the treatment of cancer.
    Type: Application
    Filed: January 31, 2019
    Publication date: April 29, 2021
    Inventors: Simon ALVIS, Magdalena KIELTYKA